Binary catalytic therapy: A new approach to treatment of malignant tumors. Results of pre-clinical and clinical studies

Novel “Oxicobalamin+Ascorbic acid,” “Teraphthal+Ascorbic acid,” and “Efiter+Ascorbic acid” binary catalytic systems (BCS) have been studied in the pre-clinical experiments and clinical trials. It was shown in experiments that Oxycobalamin, Teraphthal, and Efiter-based BCS demonstrated moderate antitumor efficiency against murine and rat transplanted tumors of various histogenesis, as well as high modifying activity for different official antistatic agents, radiotherapy, chemo-radiotherapy, and local laser-induced hyperthermia. The studied BCS had no pronounced toxicity in mice, rats, or dogs, so they were considered to be moderately hazardous pharmacologic agents. Revealed toxic and side effects of BCS were dose-dependent and totally reversible. Clinical trials of the BCS demonstrated good tolerability in cancer patients with exhausted possibilities of antitumor treatment and moderate antitumor efficacy. Partial regress and stabilization of the malignant processes were observed with various routes of catalysts administration.